|
1
|
Cohen LF, Balow JE, Magrath IT, Poplack DG
and Ziegler JL: Acute tumor lysis syndrome. A review of 37 patients
with Burkitt’s lymphoma. Am J Med. 68:486–491. 1980.
|
|
2
|
Coiffier B, Altman A, Pui CH, Younes A and
Cairo MS: Guidelines for the management of pediatric and adult
tumor lysis syndrome: an evidence-based review. J Clin Oncol.
26:2767–2778. 2008.
|
|
3
|
Cairo MS, Coiffier B, Reiter A and Younes
A; TLS Expert Panel. Recommendations for the evaluation of risk and
prophylaxis of tumour lysis syndrome (TLS) in adults and children
with malignant diseases: an expert TLS panel consensus. Br J
Haematol. 149:578–586. 2010.
|
|
4
|
Howard SC, Jones DP and Pui CH: The tumor
lysis syndrome. N Engl J Med. 364:1844–1854. 2011.
|
|
5
|
Firwana BM, Hasan R, Hasan N, Alahdab F,
Alnahhas I, Hasan S and Varon J: Tumor lysis syndrome: a systematic
review of case series and case reports. Postgrad Med. 124:92–101.
2012.
|
|
6
|
Cairo MS and Bishop M: Tumour lysis
syndrome: new therapeutic strategies and classification. Br J
Haematol. 127:3–11. 2004.
|
|
7
|
Hande KR and Garrow GC: Acute tumor lysis
syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J
Med. 94:133–139. 1993.
|
|
8
|
Will A and Tholouli E: The clinical
management of tumour lysis syndrome in haematological malignancies.
Br J Haematol. 154:3–13. 2011.
|
|
9
|
Massey V, Komai H, Palmer G and Elion GB:
On the mechanism of inactivation of xanthine oxidase by allopurinol
and other pyrazolo[3,4-d]pyrimidines. J Biol Chem. 245:2837–2844.
1970.
|
|
10
|
Faruque LI, Ehteshami-Afshar A, Wiebe N,
Tjosvold L, Homik J and Tonelli M: A systematic review and
meta-analysis on the safety and efficacy of febuxostat versus
allopurinol in chronic gout. Semin Arthritis Rheum. 43:367–375.
2013.
|
|
11
|
Bruce SP: Febuxostat: a selective xanthine
oxidase inhibitor for the treatment of hyperuricemia and gout. Ann
Pharmacother. 40:2187–2194. 2006.
|
|
12
|
Schumacher HR Jr, Becker MA, Wortmann RL,
et al: Effects of febuxostat versus allopurinol and placebo in
reducing serum urate in subjects with hyperuricemia and gout: a
28-week, phase III, randomized, double-blind, parallel-group trial.
Arthritis Rheum. 59:1540–1548. 2008.
|
|
13
|
Edwards NL: Febuxostat: a new treatment
for hyperuricaemia in gout. Rheumatology (Oxford). 48:ii15–ii19.
2009.
|
|
14
|
Burns CM and Wortmann RL: Gout
therapeutics: new drugs for an old disease. Lancet. 377:165–177.
2011.
|
|
15
|
Garcia-Valladares I, Khan T and Espinoza
LR: Efficacy and safety of febuxostat in patients with
hyperuricemia and gout. Ther Adv Musculoskelet Dis. 3:245–253.
2011.
|
|
16
|
The guideline revising committee of
Japanese Society of Gout and Nucleic Acid Metabolism. Digest of
Guideline for the management of hyperuricemia and gout. 2nd
edition. Gout Nucleic Acid Metabol. 34. pp. 107–143. 2010, (In
Japanese).
|
|
17
|
Cortes J, Moore JO, Maziarz RT, et al:
Control of plasma uric acid in adults at risk for tumor Lysis
syndrome: efficacy and safety of rasburicase alone and rasburicase
followed by allopurinol compared with allopurinol alone-results of
a multicenter phase III study. J Clin Oncol. 28:4207–4213.
2010.
|
|
18
|
Kikuchi A, Kigasawa H, Tsurusawa M, et al:
A study of rasburicase for the management of hyperuricemia in
pediatric patients with newly diagnosed hematologic malignancies at
high risk for tumor lysis syndrome. Int J Hematol. 90:492–500.
2009.
|
|
19
|
Yamauchi T, Negoro E, Lee S, et al: A high
serum uric acid level is associated with poor prognosis in patients
with acute myeloid leukemia. Anticancer Res. 33:3947–3951.
2013.
|
|
20
|
Inai K, Tsutani H and Ueda T:
Hyperuricemia associated with hematological malignancies. Gout and
Nucleic Acid Metabolism. 23:181–186. 1999.(In Japanese).
|
|
21
|
de Bont JM and Pieters R: Management of
hyperuricemia with rasburicase review. Nucleosides Nucleotides
Nucleic Acids. 23:1431–1440. 2004.
|
|
22
|
Rampello E, Fricia T and Malaguarnera M:
The management of tumor lysis syndrome. Nat Clin Pract Oncol.
3:438–447. 2006.
|
|
23
|
Andreoli SP, Clark JH, McGuire WA and
Bergstein JM: Purine excretion during tumor lysis in children with
acute lymphocytic leukaemia receiving allopurinol: relationship to
acute renal failure. J Pediatr. 109:292–298. 1986.
|
|
24
|
Navolanic PM, Pui CH, Larson RA, et al:
Elitek-rasburicase: an effective means to prevent and treat
hyperuricemia associated with tumor lysis syndrome, a Meeting
Report, Dallas, Texas, January, 2002. Leukaemia. 17:499–514.
2003.
|
|
25
|
Cheson BD and Dutcher BS: Managing
malignancy-associated hyperuricemia with rasburicase. J Support
Oncol. 3:117–124. 2005.
|
|
26
|
Arellano F and Sacristan JA: Allopurinol
hypersensitivity syndrome: a review. Ann Pharmacother. 27:337–343.
1993.
|
|
27
|
Hande KR, Noone RM and Stone WJ: Severe
allopurinol toxicity: Description and guidelines for prevention in
patients with renal insufficiency. Am J Med. 76:47–56. 1984.
|
|
28
|
Khosravan R, Grabowski BA, Mayer MD, Wu
JT, Joseph-Ridge N and Vernillet L: The effect of mild and moderate
hepatic impairment on pharmacokinetics, pharmacodynamics and safety
of febuxostat, a novel non-purine selective inhibitor of xanthine
oxidase. J Clin Pharmacol. 46:88–102. 2006.
|
|
29
|
Becker MA, Schumacher HR, Espinoza LR,
Wells AF, MacDonald P, Lloyd E and Lademacher C: The urate-lowering
efficacy and safety of febuxostat in the treatment of the
hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther.
12:R632010.
|
|
30
|
Vadhan-Raj S, Fayad LE, Fanale MA, et al:
A randomized trial of a single-dose rasburicase versus five-daily
doses in patients at risk for tumor lysis syndrome. Ann Oncol.
23:1640–1645. 2012.
|
